The Technical AnalystExchange: EURONEXT Sector: Healthcare Industry: Medical Care Facilities
Oncoclínicas do Brasil Price, Forecast, Insider, Ratings, Fundamentals & Signals
10.47% BRL7.07
America/New_York / 17 mai 2024 @ 16:10
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 593.64 mill |
| EPS: | 0.390 |
| P/E: | 18.13 |
| Earnings Date: | Aug 13, 2024 |
| SharesOutstanding: | 508.29 mill |
| Avg Daily Volume: | 4.35 mill |
| RATING 2024-05-17 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.06x |
| Company: PE 18.13 | sector: PE 17.08 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.60x |
| Company: PE 18.13 | industry: PE 30.09 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
BRL 6.70 - 7.45 ( +/- 5.30%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | BRL7.07 (10.47% ) |
| Volume | 11.29 mill |
| Avg. Vol. | 4.35 mill |
| % of Avg. Vol | 259.73 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ONCO3.SA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ONCO3.SA
Oncoclínicas do Brasil Serviços Médicos S.A. provides medical services focused on clinical oncology and radiotherapy in Latin America. It offers services in the areas of chemotherapy, radiotherapy, hormone therapy, molecular target drugs, immunotherapy, bone marrow transplant, catheter heparinization, non-oncological infusions, laser therapy, myelogram - bone marrow biopsy, continuous care, and precision medicine. The company was founded in 2010 and is based in São Paulo, Brazil.